TY - JOUR
T1 - Safety of regadenoson stress testing in patients with pulmonary hypertension
AU - Moles, Victor M.
AU - Cascino, Thomas
AU - Saleh, Ashraf
AU - Mikhova, Krasimira
AU - Lazarus, John J.
AU - Ghannam, Michael
AU - Yun, Hong J.
AU - Konerman, Matthew
AU - Weinberg, Richard L.
AU - Ficaro, Edward P.
AU - Corbett, James R.
AU - McLaughlin, Vallerie V.
AU - Murthy, Venkatesh L.
N1 - Publisher Copyright:
© 2016, American Society of Nuclear Cardiology.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.
AB - Objectives: We sought to determine the safety of regadenoson stress testing in patients with PH. Background: PH is increasingly recognized at more advanced ages. As many as one-third of patients with PH have coronary artery disease. Because of their physical limitations, patients with PH are unable to adequately exercise. Regadenoson can potentially have an adverse impact due to their tenuous hemodynamics. Current guidelines suggest performing a coronary angiography in patients with PH who have angina or multiple coronary risk factors. Methods: We identified 67 consecutive patients with confirmed PH by catheterization (mean PA > 25 mmHg not due to left heart disease) who underwent MPI with regadenoson stress. Medical records were reviewed to determine hemodynamic and ECG response to regadenoson. Results: No serious events occurred. Common side effects related to regadenoson were observed, dyspnea being the most common (70.6%). No syncope occurred. Heart rate increased from 74.6 ± 14 to 96.3 ± 18.3 bpm, systolic blood pressure increased from 129.8 ± 20.9 to 131.8 ± 31 mmHg, and diastolic blood pressure decreased from 77.1 ± 11.4 to 72.9 ± 15.3 mmHg. There was no ventricular tachycardia, ventricular fibrillation, or second- or third-degree atrioventricular block. Conclusion: Regadenoson stress MPI appears to be well tolerated and safe in patients with PH.
KW - Pulmonary hypertension
KW - coronary artery disease
KW - pulmonary arterial hypertension
KW - regadenoson
KW - stress test
UR - http://www.scopus.com/inward/record.url?scp=84997770350&partnerID=8YFLogxK
U2 - 10.1007/s12350-016-0734-6
DO - 10.1007/s12350-016-0734-6
M3 - Article
C2 - 27896702
AN - SCOPUS:84997770350
SN - 1071-3581
VL - 25
SP - 820
EP - 827
JO - Journal of Nuclear Cardiology
JF - Journal of Nuclear Cardiology
IS - 3
ER -